Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare CVE:ABCNASDAQ:HCM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABCABcann GlobalC$0.00C$0.00▼C$0.00N/AN/AN/AN/AHCMHUTCHMED$15.74+3.6%$14.94$11.51▼$21.92$2.74B0.66106,787 shs83,677 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHCMHUTCHMED+3.55%+14.39%+7.66%+16.08%-14.50%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABCABcann GlobalN/AN/AN/AN/AN/AN/AN/AN/AHCMHUTCHMED1.3298 of 5 stars2.03.00.00.01.80.01.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABCABcann Global 0.00N/AN/AN/AHCMHUTCHMED 2.00Hold$19.0020.71% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABCABcann GlobalN/AN/AN/AN/AN/AN/AHCMHUTCHMED$630.20M4.35$0.64 per share24.51$4.27 per share3.69Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABCABcann GlobalN/AN/A0.00N/AN/AN/AN/AN/AN/AHCMHUTCHMED$100.78MN/A0.0010.78N/AN/AN/AN/A5/9/2025 (Estimated)Compare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABCABcann GlobalN/AN/AN/AN/AN/AHCMHUTCHMEDN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABCABcann GlobalN/AN/AN/AHCMHUTCHMED0.072.812.68Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABCABcann GlobalN/AHCMHUTCHMED8.82%Insider OwnershipCompanyInsider OwnershipABCABcann GlobalN/AHCMHUTCHMED3.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABCABcann GlobalN/AN/AN/ANot OptionableHCMHUTCHMED1,760174.32 million168.04 millionNot OptionableUPR, UDG, ABC, and HCM HeadlinesRecent News About These CompaniesHUTCHMED (NASDAQ:HCM) Shares Gap Up - Time to Buy?April 24 at 12:15 PM | marketbeat.comHUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025April 23 at 8:00 PM | globenewswire.comHUTCHMED shares rise 10% as Phase II gastric cancer trial hits key milestoneApril 22 at 4:12 AM | proactiveinvestors.co.ukHUTCHMED Completes Enrollment for Savolitinib Phase II Study in Gastric CancerApril 21, 2025 | tipranks.comHUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in ChinaApril 21, 2025 | manilatimes.netHUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in ChinaApril 21, 2025 | globenewswire.comHUTCHMED (NASDAQ:HCM) Shares Gap Down - What's Next?April 17, 2025 | marketbeat.comHUTCHMED (NASDAQ:HCM) Trading Up 6.9% - Time to Buy?April 16, 2025 | marketbeat.comBristol Myers Squibb Provides Update on Phase 3 ODYSSEY-HCM TrialApril 14, 2025 | businesswire.comHUTCHMED (NASDAQ:HCM) Shares Gap Up - What's Next?April 11, 2025 | marketbeat.comHUTCHMED (NASDAQ:HCM) Shares Up 8.3% - Here's WhyApril 10, 2025 | marketbeat.comHUTCHMED (NASDAQ:HCM) Shares Gap Down - Should You Sell?April 9, 2025 | marketbeat.comWhy HUTCHMED (China) Limited’s (HCM) Stock Is Down 15.68%April 8, 2025 | aaii.com3 Internet Delivery Services Stocks in Focus Amid Industry ChallengesApril 8, 2025 | zacks.comHUTCHMED (NASDAQ:HCM) Trading Up 7.5% - Here's WhyApril 3, 2025 | marketbeat.comHUTCHMED (China) Limited (NASDAQ:HCM) Shares Sold by Schroder Investment Management GroupApril 3, 2025 | marketbeat.comEdgewise Therapeutics Sees Meaningful HCM Treatment Gains With EDG-7500 In Phase 2 StudyApril 2, 2025 | benzinga.comHUTCHMED (NASDAQ:HCM) Shares Gap Up - Here's WhyMarch 28, 2025 | marketbeat.comHUTCHMED (NASDAQ:HCM) Shares Gap Down - Time to Sell?March 26, 2025 | marketbeat.comTerrestrial Energy to Become First Publicly Traded Molten Salt Nuclear Reactor Developer Through Combination with HCM II Acquisition Corp.March 26, 2025 | globenewswire.comHutchmed says NDA for Tazverik granted conditional approval in ChinaMarch 21, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAre Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?Signs of a more buyer-friendly housing market emerge for the spring homebuying seasonBy The Associated Press | April 6, 2025View Signs of a more buyer-friendly housing market emerge for the spring homebuying season5 Highest-Rated Dividend Stocks According to MarketBeatBy Thomas Hughes | April 10, 2025View 5 Highest-Rated Dividend Stocks According to MarketBeat3 Stocks Near 52-Week Lows With Strong Rebound PotentialBy Gabriel Osorio-Mazilli | March 31, 2025View 3 Stocks Near 52-Week Lows With Strong Rebound PotentialD-Wave: Multiple Use Cases Emerge Following Quantum SupremacyBy Nathan Reiff | April 1, 2025View D-Wave: Multiple Use Cases Emerge Following Quantum SupremacyUPR, UDG, ABC, and HCM Company DescriptionsABcann Global CVE:ABCHUTCHMED NASDAQ:HCM$15.74 +0.54 (+3.55%) As of 04/24/2025 04:00 PM EasternHUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Now Is the Time to Buy ServiceNow—The Rebound Is Real Seismic Shift at Intel: Massive Layoffs Precede Crucial Earnings Rocket Lab Lands New Contract, Builds Momentum Ahead of Earnings Netflix’s Trillion-Dollar Baby Ambition: Realistic or Ridiculous? Chip Giant ASML Gets New Price Targets With Big Upside Salesforce Is Ready to Rebound With Analysts Forecasting Upside What's Behind Bill Ackman Buying Hertz Stock? S&P 500 and Nasdaq-100 Flashed Death Crosses—Should You Worry? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
